Global Ocular Pain Periocular Treatment Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Ocular Pain Periocular Treatment Market Size

• The global ocular pain periocular treatment market size was valued at USD 47.2 million in 2024 and is expected to reach USD 84.30 million by 2032, at a CAGR of 7.52% during the forecast period
• The market growth is largely fueled by the rising prevalence of ocular disorders, post-surgical complications, and the increasing adoption of periocular injections and nerve block techniques for effective pain management
• Furthermore, growing demand for safer, targeted, and long-acting therapies, along with advancements in periocular drug-delivery systems, is positioning periocular treatments as a preferred approach for managing ocular pain. These converging factors are accelerating clinical adoption and boosting the industry’s growth globally

Ocular Pain Periocular Treatment Market Analysis

• Ocular pain periocular treatments, including periocular injections, nerve blocks, and topical periocular formulations, are becoming essential components of modern ophthalmic care due to their targeted pain relief, minimal systemic side effects, and growing use in both surgical and chronic eye conditions
• The increasing demand for these treatments is primarily fueled by the rising prevalence of ocular disorders, a higher volume of ophthalmic surgeries, and growing clinical adoption of long-acting periocular drug-delivery systems for improved pain management outcomes
• North America dominated the ocular pain periocular treatment market with the largest revenue share of 39.5% in 2024, supported by advanced healthcare infrastructure, strong reimbursement frameworks, and early adoption of innovative pain management techniques, with the U.S. witnessing substantial uptake in periocular corticosteroid injections and nerve block procedures across major ophthalmic centers
• Asia-Pacific is expected to be the fastest-growing region in the ocular pain periocular treatment market during the forecast period, projected to expand at a CAGR of over 9.5%, driven by rising awareness of ocular health, increasing surgical volumes, and expanding access to specialized ophthalmic care
• The periocular injection segment dominated the ocular pain periocular treatment market with a market share of 42.1% in 2024, driven by its effectiveness in post-operative pain control, established clinical acceptance, and the development of sustained-release corticosteroid and anesthetic formulations that provide longer-lasting relief

Report Scope and Ocular Pain Periocular Treatment Market Segmentation           

Ocular Pain Periocular Treatment Market Trends

Rising Adoption of Sustained-Release Periocular Drug Delivery Systems

• A significant and accelerating trend in the global ocular pain periocular treatment market is the growing shift toward sustained-release periocular injections and implants, offering targeted, long-lasting pain relief with reduced dosing frequency
• For instance, periocular corticosteroid depots and biodegradable implants are being developed to maintain therapeutic drug levels for weeks or months, reducing the burden of repeat injections on patients and providers
• Sustained-release systems enable consistent pain control after surgeries and in chronic conditions, while also lowering systemic side effects compared to oral or systemic medications, improving treatment safety profiles
• For instance, several microsphere-based and nanocarrier periocular delivery technologies are being tested to optimize bioavailability and enhance efficacy in managing post-operative and neuropathic ocular pain
• The seamless integration of sustained-release periocular treatments into ophthalmic practice is facilitating reduced clinic visits, lower healthcare costs, and greater patient adherence, especially in elderly and chronic care populations
• This trend towards more effective, durable, and patient-friendly periocular therapies is fundamentally reshaping ophthalmic pain management expectations, driving innovation among biotech and pharma companies
• The demand for periocular pain treatments that deliver sustained relief with improved convenience is growing rapidly across both surgical and chronic care settings, as patients and providers increasingly prioritize long-term therapeutic outcomes

Ocular Pain Periocular Treatment Market Dynamics

Driver

Growing Need Due to Rising Ophthalmic Surgeries and Pain Management Demand

• The increasing global prevalence of ocular disorders such as cataracts, glaucoma, and uveitis, coupled with the rising number of ophthalmic surgeries, is a significant driver for heightened demand for periocular pain treatments
• For instance, in March 2024, several ophthalmic centers in the U.S. adopted periocular corticosteroid injections as standard post-operative protocols for cataract and vitreoretinal surgeries, accelerating treatment uptake
• As patients and physicians seek safer, more localized alternatives to systemic analgesics, periocular treatments provide targeted relief with fewer complications, offering a compelling upgrade over traditional pain management methods
• Furthermore, the growing clinical acceptance of periocular nerve blocks and depot injections is making them integral components of ophthalmic surgical care, offering superior outcomes in pain control
• The convenience of longer-acting periocular formulations, reduced systemic exposure, and the ability to manage complex pain in outpatient settings are key factors propelling adoption across global ophthalmic practices.
• • The trend toward advanced periocular drug delivery platforms and their increasing inclusion in standard care pathways further contribute to sustained market growth

Restraint/Challenge

Procedure-Related Risks and Regulatory Compliance Hurdle

• Concerns surrounding the potential risks of periocular injections, such as infection, hemorrhage, and inadvertent ocular injury, pose a significant challenge to broader adoption in some patient populations
• For instance, high-profile reports of complications following periocular corticosteroid injections have made certain clinicians and patients cautious about adopting these therapies
• Addressing these safety concerns through improved injection techniques, safer delivery devices, and rigorous training is crucial for building confidence in periocular treatments as a mainstream pain management option
• For instance, companies developing periocular depots and microsphere systems emphasize their controlled-release safety data and minimally invasive delivery in clinical trials to reassure healthcare providers
• In addition, the relatively high cost of novel periocular drug-delivery technologies compared to conventional eye drops or systemic analgesics can be a barrier to adoption, particularly in cost-sensitive healthcare systems
• While sustained-release periocular products offer long-term value, upfront expenses and strict regulatory approval requirements can still hinder widespread use, especially in emerging markets with limited reimbursement support
• Overcoming these challenges through technological innovation, physician training, and expanded insurance coverage will be vital for sustained market penetration and growth

Ocular Pain Periocular Treatment Market Scope

The market is segmented on the basis of treatment, indication, end user, and distribution channel.

• By Treatment

On the basis of treatment, the ocular pain periocular treatment market is segmented into periocular nerve blocks & regional anaesthesia, periocular injections, topical periocular agents & ointments, and adjunct therapies. Periocular Injections dominated the market with the largest revenue share of 42.1% in 2024, driven by their widespread use in post-operative pain control and inflammatory eye conditions. These injections provide targeted delivery of corticosteroids and anesthetics, offering longer-lasting relief compared to topical alternatives. Hospitals and specialty clinics prefer injections due to their proven efficacy, ability to bypass systemic side effects, and compatibility with sustained-release drug technologies. Growing innovation in depot formulations and microsphere-based periocular delivery systems is further strengthening this segment’s position.

Adjunct therapies are anticipated to witness the fastest growth rate during the forecast period, supported by ongoing advancements in periocular drug-delivery implants and minimally invasive devices. The development of biodegradable depots and sustained-release microspheres is revolutionizing pain management by reducing the frequency of clinical visits. In addition, increased research into novel biologics and combination therapies delivered via adjunct systems is expanding their adoption. Rising demand for safer, durable, and patient-friendly alternatives makes adjunct therapies the most attractive growth opportunity in the coming years.

• By Indication

On the basis of indication, the ocular pain periocular treatment market is segmented into post-operative pain, acute trauma, inflammatory ocular conditions, neuropathic / chronic ocular surface pain, and infection-related pain. Post-Operative Pain held the largest market revenue share in 2024, driven by the rising global volume of cataract, refractive, and vitreoretinal surgeries. Periocular treatments such as corticosteroid injections and nerve blocks are widely integrated into post-surgical protocols to ensure patient comfort and minimize recovery complications. Hospitals and ASCs strongly rely on periocular therapies due to their targeted action, reduction in systemic drug exposure, and clinical validation across multiple ophthalmic procedures. This segment continues to dominate as surgical volumes increase worldwide.

Neuropathic / chronic ocular surface pain is expected to register the fastest growth rate over the forecast period, fueled by increasing recognition of corneal neuropathic pain and ocular surface disease. Traditional topical therapies often provide insufficient relief, creating demand for localized periocular treatments with long-lasting analgesic effects. Advances in sustained-release anesthetics and innovative nerve-block techniques are addressing this unmet clinical need. Rising patient awareness and growing research into chronic ocular pain mechanisms are expanding this segment’s adoption rapidly.

• By End User

On the basis of end user, the ocular pain periocular treatment market is segmented into hospitals, specialty eye clinics / ophthalmology practices, ambulatory surgery centers (ASCs), and homecare. Hospitals dominated the market with the largest revenue share in 2024, owing to their central role in conducting high volumes of ophthalmic surgeries and post-operative care. Hospitals have greater access to advanced periocular injection therapies, nerve block procedures, and novel drug-delivery systems compared to smaller settings. The presence of trained ophthalmologists and anesthesiologists ensures safe administration of periocular treatments, further cementing hospitals as the leading end-user segment. Their ability to handle complex ocular pain cases sustains their market leadership.

Ambulatory surgery centers (ASCs) are anticipated to grow at the fastest CAGR during forecast period, supported by the global shift toward outpatient and minimally invasive surgical care. ASCs offer cost-effective environments for cataract and refractive surgeries, where periocular treatments are increasingly used for pain management. Their flexibility, shorter recovery times, and focus on efficiency are attracting patients away from traditional hospitals. The expansion of specialized ophthalmic ASCs in both developed and emerging markets makes this segment the fastest growing during the forecast horizon.

• By Distribution Channel

On the basis of distribution channel, the ocular pain periocular treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and direct sales. Hospital Pharmacies accounted for the largest market revenue share in 2024, primarily because periocular treatments such as corticosteroid injections and anesthetics are typically administered within hospital settings. Hospital pharmacies ensure immediate access to essential ophthalmic drugs, streamlined procurement for surgical procedures, and regulatory compliance for high-risk injectable products. Their integral role in hospital-based care pathways keeps them the dominant channel for periocular pain therapies.

Online pharmacies are projected to grow at the fastest rate over the forecast period, driven by rising digitalization in healthcare and patient demand for convenient access to topical periocular agents and adjunct therapies. Increasing consumer trust in e-pharmacy platforms, coupled with home delivery options, is expanding online sales. In addition, the availability of OTC ointments, gels, and lubricants through digital channels is accelerating adoption. The integration of tele-ophthalmology consultations with e-pharmacy delivery further strengthens this channel’s rapid growth trajectory.

Ocular Pain Periocular Treatment Market Regional Analysis

• North America dominated the ocular pain periocular treatment market with the largest revenue share of 39.5% in 2024, supported by advanced healthcare infrastructure, strong reimbursement frameworks, and early adoption of innovative pain management techniques
• Patients and providers in the region highly value the targeted pain relief, reduced systemic side effects, and clinical efficacy offered by periocular therapies compared to conventional systemic analgesics
• This widespread adoption is further supported by advanced healthcare infrastructure, favorable reimbursement frameworks, and a growing preference for minimally invasive, long-acting treatments, establishing periocular therapies as a favored solution across hospitals, ASCs, and specialty eye clinics

U.S. Ocular Pain Periocular Treatment Market Insight

The U.S. ocular pain periocular treatment market captured the largest revenue share of 79% in 2024 within North America, fueled by a high incidence of post-operative ocular pain and trauma-related cases. Patients are increasingly prioritizing targeted periocular therapies over systemic analgesics due to their reduced side effects and improved efficacy. The growing preference for minimally invasive pain control techniques, combined with strong adoption of ambulatory surgeries, further propels market demand. Moreover, the integration of advanced periocular injections and nerve block procedures in ophthalmology practices is significantly contributing to market expansion.

Europe Ocular Pain Periocular Treatment Market Insight

The Europe ocular pain periocular treatment market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by the rising prevalence of inflammatory ocular disorders and expanding surgical interventions. The increase in aging population, coupled with greater awareness of eye health, is fostering adoption of periocular treatments. European patients are also drawn to the improved recovery outcomes and localized pain relief these therapies provide. The region is experiencing significant uptake across hospitals, specialty eye clinics, and ASCs, with periocular options being increasingly incorporated into post-surgical care protocols.

U.K. Ocular Pain Periocular Treatment Market Insight

The U.K. ocular pain periocular treatment market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by the escalating demand for advanced ophthalmic care and a focus on enhancing patient comfort. In addition, concerns regarding surgical complications and post-treatment pain are encouraging ophthalmologists to adopt periocular solutions. The U.K.’s well-developed healthcare infrastructure, alongside expanding access through specialty clinics, is expected to stimulate further growth.

Germany Ocular Pain Periocular Treatment Market Insight

The Germany ocular pain periocular treatment market is expected to expand at a considerable CAGR during the forecast period, fueled by strong innovation in ophthalmology and demand for effective pain management protocols. Germany’s advanced healthcare infrastructure, combined with its emphasis on patient safety and innovation, promotes the adoption of periocular injections and nerve block solutions. The integration of such therapies into multi-specialty hospitals is also becoming increasingly prevalent, aligning with consumer expectations for quality-driven outcomes.

Asia-Pacific Ocular Pain Periocular Treatment Market Insight

The Asia-Pacific ocular pain periocular treatment market is poised to grow at the fastest CAGR of 9.5% during the forecast period of 2025 to 2032, driven by a high burden of ophthalmic surgeries and rising trauma cases in countries such as China, Japan, and India. The region’s growing healthcare investments, supported by government initiatives for affordable eye care, are driving adoption. Furthermore, as APAC emerges as a hub for ophthalmology innovation and training, the accessibility of periocular therapies is expanding to a broader patient base.

Japan Ocular Pain Periocular Treatment Market Insight

The Japan ocular pain periocular treatment market is gaining momentum due to the country’s high prevalence of ocular surgeries and its focus on cutting-edge medical practices. The Japanese market places significant emphasis on minimally invasive pain control, and adoption is driven by rising demand for improved recovery outcomes. The integration of periocular therapies with advanced ophthalmic care systems is fueling growth. Moreover, Japan’s aging population is such asly to spur demand for effective and safer ocular pain treatments in both hospital and outpatient settings.

India Ocular Pain Periocular Treatment Market Insight

The India ocular pain periocular treatment market accounted for the largest market revenue share in Asia-Pacific in 2024, attributed to the country’s high surgical volume, rapid urbanization, and growing middle-class population. India stands as one of the largest markets for ophthalmic care, and periocular treatments are becoming increasingly common in both public and private facilities. The push towards expanding specialty eye clinics and availability of cost-effective periocular solutions, alongside strong domestic medical players, are key factors propelling the market in India.

Ocular Pain Periocular Treatment Market Share

The ocular pain periocular treatment industry is primarily led by well-established companies, including:

• OKYO Pharma, Limited (U.K.)
• EyePoint Pharmaceuticals, Inc. (U.S.)
• Santen Pharmaceutical Co., Ltd. (Japan)
• Bausch + Lomb. (U.S.)
• Alcon Inc. (Switzerland)
• Ocular Therapeutix, Inc. (U.S.)
• KALA BIO (U.S.)
• Aldeyra Therapeutics, Inc. (U.S.)
• Dompé (Italy)
• Sun Pharmaceutical Industries Ltd. (India)
• Glaukos Corporation (U.S.)
• Tarsus Pharmaceuticals, Inc. (U.S.)
• Novartis AG (Switzerland)
• RecensMedical (U.S.)
• Alteogen, Inc. (South Korea)
• Regeneron Pharmaceuticals Inc. (U.S.)
• Johnson & Johnson and its affiliates (U.S.)
• Aerie Pharmaceuticals, Inc. (U.S.)
• Ocuphire Pharma, Inc. (U.S.)
• Nicox S.A. (France)

What are the Recent Developments in Global Ocular Pain Periocular Treatment Market?

• In May 2025, EyeCool Therapeutics reported positive results from a pilot randomized double-masked trial of its investigational device ETX-4143, which gently cools the ocular surface for 4 minutes to treat chronic ocular surface pain (COSP). Many patients experienced immediate relief and lasting improvement over subsequent weeks
• In May 2025, OKYO Pharma’s small molecule urcosimod received Fast Track designation from the U.S. FDA for the treatment of neuropathic corneal pain (NCP), accelerating its regulatory pathway and increasing the such aslihood of expedited review
• In October 2024, OKYO Pharma announced that the first patient has been dosed in a Phase 2 clinical trial of OK-101, a novel non-opioid topical candidate for neuropathic corneal pain (NCP). OK-101 is designed with a lipid anchor to prolong ocular surface residence time, aiming to provide sustained analgesic effect in a condition with no FDA-approved treatments
• In September 2024, ophthalmic contract research organization Ora partnered with the Institute of Eye Surgery in Ireland to accelerate patient access and clinical trial capability for new ophthalmology therapies. This collaboration strengthens the European clinical research infrastructure, which could support faster development and delivery of periocular pain treatments
• In July 2023, OKYO Pharma announced a clinical trial agreement with Tufts Medical Center to conduct a 40-patient open-label trial of its investigational drug OK-101 for neuropathic corneal pain, collaborating directly with Dr. Pedram Hamrah at Tufts as Principal Investigator

SKU-74631